Post marketing surveillance on safety and effectiveness of ANGIPARS in treatment of diabetic foot ulcers

Daru

Volumn 17, Issue SUPPL. 1, 2009, Pages 45-49

  Ebrahimi, M ^a   Bakhshayeshi, S ^a   Heshmat, R ^a   Shahbazi, S ^a   Aala, M ^a   Peimani, M ^a   Khushechin, G ^a   Mohajeri Tehrani, M R ^a   Shojaeefard, A ^b   Kamali, K ^c   Azimaraghi, O ^a   Larijani, B ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ANGIPARS; Effectiveness; Post marketing surveillance; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ANGIPARS; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CHOLESTEROL; CREATININE; HERBACEOUS AGENT; PHOSPHORUS; SODIUM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANKLE BRACHIAL INDEX; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; BLOOD EXAMINATION; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEBRIDEMENT; DIABETIC FOOT; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 4 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POSTMARKETING SURVEILLANCE; PRESSURE MEASUREMENT; PROTHROMBIN TIME; SIDE EFFECT; SODIUM BLOOD LEVEL; TEMPERATURE; THROMBOCYTE COUNT; TOE BRACHIAL INDEX; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WOUND TEMPERATURE;

EID: 75449098070     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Allman RM. Pressure ulcer prevalence, incidence, risk factors, and impact. Clin Geriatr Med 1997; 13(3): 421-36.
2. Allman RM, Goode PS, Burst N, Bartolucci AA, Thomas DR. Pressure ulcers, hospital complications, and disease severity: impact on hospital costs and length of stay. Adv Wound Care 1999; 12(1): 22-30.
3. Reuler JB, Cooney TG. The pressure sore: pathophysiology and principle of management. Ann Intern Med 1981; 94: 661- 666.
4. American Diabetes Association: Poistion Statement: Consensus Development Conference on Diabetic Foot Wound Care. Diabetes Care 1999; 22(8): 1354-60.
5. Reddy M, Gill SS, Rochon PA. Preventing pressure ulcers: a systematic review. JAMA 2006; 296: 974-984.
6. Valls MD, Cronstein BN, Montesinos MC. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol 2009; 77(7): 1117-24.
7. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess 2000; 4(21): 1-237.
8. Larijani B, Hasani Ranjbar S. Overview of diabetic foot; novel treatments in diabetic foot ulcer. DARU 2008; 16 (Suppl.1): 1-6.
9. Diegelmann RF, Evans MC. Wound healing: An overview of acute, fibrotic and delayed healing. Frontiers in Bioscience 2004; 9: 283-289.
10. Keller BP, Wille J, Ramshorst BV, Werken CVD. Pressure ulcers in intensive care patients: a review of risks and prevention. Intensive Care Med 2002; 28(10): 1379-88.
11. Allman RM. The impact of pressure ulcers on health care costs and mortality. Adv Wound Care1998; 11(3 suppl):2.
12. Mast BA, Diegelmann B. Wound healing; biochemical and clinical aspects. The Skin 1992; 344.
13. Dalla Paola L, Faglia E. Treatment of diabetic foot ulcer: an overview strategies for clinical approach. Curr Diabetes Rev 2006; 2 (4): 431-47.
14. Shih CC, Wu YW, Lin WC. Antihyperglycemic and antioxidant properties of Anoectochilus Formosanus in diabetic rats. Clin Exp pharmacol 2002; 29: 684-8.
15. Naziroglu M, Butterworth P. Protective effects of moderate exercise with dietary vitamin C and E on blood antioxidative defense mechanism in rats with streptozotocin-induced diabetes. Can J Appl Physiol 2005; 30 (2): 172-85.
16. Penckofer S, Schwertz D, Florczak K. Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and prooxidants. J Cardiovasc Nurs 2002; 16 (2): 68-85.
17. Chanwitheesuk A, Teerawutgulrag A, Rakariyatham N. Screening of antioxidant activity and antioxidant compounds of some edible plants of Thailand. Food Chem 2005; 92: 491-7.
18. Larkins N, Wynn S. Pharmacognosy: Phytomedicines and their mechanisms. Vet Clin North Am Small Anim Pract 2004; 34(1): 291-327.
19. Brem H, Kodra A, Golinko MS, Entero H, Stojadinovic O, et al. Mechanism of Sustained Release of Vascular Endothelial Growth Factor in Accelerating Experimental Diabetic Healing. J Invest Dermatol 2009; 129: 2275-2287.
20. Komarcević A. The modern approach to wound treatment. Med Pregl 2000; 53(7-8): 363-8.
21. Larijani B, Heshmat R, Bahrami A, Delshad H, Ranjbar Omrani G, Mohammad K, et al. Effects of intravenous Semelil (ANGIPARS™) on diabetic foot ulcers healing: a multicenter clinical trial. DARU2008; 16 (suppl.1): 35-40.
22. Masoompour SM, Bagheri MH, Borhani Haghighi A, Novitsky YA, Sadeghi B, Gharibdoust F, et al. Effect of ANGIPARS™, a new herbal drug on diabetic foot ulcer : A phase 2 clinical study. DARU 2008; 16 (suppl.1): 31-34.
23. Shamimi Nouri K, Karimian R, Nasli E, Kamali K, Chaman R, Farhadi M, et al. Topical application of Semelil (ANGIPARS™) in treatment of pressure ulcers: A randomized clinical trial. DARU 2008; 16 (Suppl.1): 54-57.
24. Shamimi Nouri K, Heshmat R, Karimian R, Nasli E, Larijani B, Novitsky YA, et al. Intravenous ANGIPARS™ as a novel therapy for pressure ulcer: A randomized clinical trial. DARU 2008; 16 (suppl.1): 49-53.
25. Bahrami A, Kamali K, Ali- Asgharzadeh A, Hosseini P, Heshmat R, Khorram Khorram HR, et al. Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial. DARU 2008; 16 (suppl.1): 41-48.
26. Heshmat R, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, et al. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS™)in patients with diabetic foot ulcer: A Phase I clinical trial. DARU 2008; 16 (suppl.1): 25-30.
27. Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky YA, et al. Sub- chronic toxicity study of a novel herbal- based formulation(Semelil) on dogs .DARU 2008; 16 ( Suppl.1):15-19.
28. Abdollahi M, Farzamfar B, Salari P, Khorram Khorshid HR, Larijani B, Farhadi M, et al. Evaluation of acute and sub-chronic toxicity of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing in rodents. DARU 2008; 16 (Suppl.1):7-14.
29. Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salari P, Farzamfar B, et al. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARSTM). DARU 2008; 16 (Suppl.1): 20-24.